177 views
Photo from CLAR

CapitaLand Ascendas REIT to transform San Diego office property into a life science building

The cost of the convert-to-suit exercise will be $56.4m.

CapitaLand Ascendas REIT (CLAR) will transform its office property in  Sorrento Mesa, San Diego, California to become the new global headquarters of Crinetics Pharmaceuticals, Inc.

The cost of the convert-to-suit exercise will be $56.4m. Under the lease agreement, CLAR will convert its property into a two-storey life sciences building outfitted with new mechanical, electrical and plumbing (MEP) systems, roof, windows and interior improvements, which include state-of-the-art laboratories, office and vivarium spaces.

The 94,230 sq ft property will also have solar panels and extensive indoor and outdoor spa-like amenities to improve employee well-being. CLAR plans to complete the conversion by Q423.

When completed, the conversion will enable CLAR to ascribe a higher base rent with an annual escalation of 3% and a net property income yield pick-up of approximately 9%.

CLAR added that the triple-net lease commitment of 11.5 years, with an option to extend two additional five-year terms, by Crinetics Pharmaceuticals will provide a stable income stream.
 

Join Singapore Business Review community

Follow the link for more news on

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.